Outcomes Comparison of IV Antimicrobials in an Office Infusion Center vs. Home Care Services

SAN DIEGO, CA (October 19, 2012) – A retrospective review was conducted of randomly selected records for patients treated in four Infectious Disease POICs from January 2010-December 2011, to compare patient management and outcomes in the POIC versus HC settings. Eighty patients were evaluated with 40 HC patients, 10 from each of the four POICs, case controlled with 10 POIC patients from each of the 4 sites. Treatment success was 100% in both groups, although cure (not requiring further intervention) was slightly higher in the POIC group (68% vs. 60%). Three patients (8%) in the HC group were admitted to the hospital for worsening infection, versus two patients (5%) in the POIC group. Reported adverse events related to intravenous antibiotics (IVAB) were similar in both groups, 8 (20%) and 11 (28%) for HC and POIC, respectively. Two patients (5%) in the POIC group were admitted to the hospital during treatment due to pain and infected prosthesis removal, whereas four patients (10%) in the HC group were admitted to the hospital during treatment. There were two catheter related infections in the HC group and none in the POIC group. Outcomes upon completion of treatment were similar; however laboratory data were not obtained in nearly half of the HC patients, which was highly significant (p < 0.05). The inability for the physician to closely monitor IVAB and catheter care in HC patients raises concerns for the overall safety of this modality when considered over a large number of patients.

This study was presented at the 1st annual IDWeek™. For a printed copy of this research poster study, please call 1.866.654.2451 or email [email protected].

Healix is the national leader in the delivery of parenteral services to medical facilities. The privately-held company is based in Sugar Land, Texas, and offers customizable, turn-key solutions to help healthcare providers offer streamlined infusion therapy and related care.

ABOUT IDWeek 2012
IDWeek 2012 is the first joint annual meeting of the Infectious Diseases Society of America (IDSA), the Society for Healthcare Epidemiology of America (SHEA), the HIV Medicine Association (HIVMA), and the Pediatric Infectious Diseases Society (PIDS). With the theme—Advancing Science, Improving Care—IDWeek will feature the latest science and bench-to-bedside approaches in prevention, diagnosis, treatment, and epidemiology of infectious diseases, including HIV, across the lifespan. IDWeek 2012 takes place October 17-21 at the San Diego Convention Center in San Diego, California.

For more information, visit www.idweek.org.

Lucinda J. Van Anglen, PharmD
Healix, Inc.
t: 281.295.4000
e: [email protected]

View All

Phase II and Phase III Studies

Healix regularly and actively supports Phase II and Phase III clinical trials in each of our specialty areas, including active studies in therapies for COVID-19, Multiple Sclerosis and Intestinal Bowel Disease.

For information on partnering with Healix on a study, please contact us.